AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E400092-T1: [Translated] METHOD AND SYSTEM FOR DEMODULATION OF GPS SIGNALS

A GPS receiver uses the energy of the L1 and L2 GPS satellite signals to track the phase of the L1 and L2 P-code and the carrier phase of the L2 signal. The in-phase channel of the L1 signal, after L1 carrier demodulation with the aid of the publicly known C/A code, is first correlated with the P-code from a P-code generator in the L1 channel of the receiver. The correlation output is filtered over two W-bit periods, using an integrate-and-dump (I&D) filter, to determine whether a polarity change has occurred. Similarly the in-phase and quadrature channels of the received L2 Y-code signal are correlated with the P-code from the P-code generator in the receiver L2 channel and I&D filtered over the corresponding period of two W-bits. Polarity transitions between the two W-bits over the I&D integration period are detected by a threshold comparison with the I&D output of the L1 punctual P-code correlation signal. If a polarity change has occurred, the L1 and L2 I&D outputs are not used for L2 carrier demodulation. When there is no polarity change, the I&D output of the L1 in-phase Punctual P-code correlation is combined with the L2 in-phase Punctual P-code correlation in accordance with the L1 and L2 signal power ratio. This summed signal is multiplied with the I&D output of the L2 quadrature channel early-late P-code correlation to obtain a product signal that provides an estimate of the L2 carrier phase.
National Household Survey on Drug Abuse (NHSDA-1996)

<p>This series measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions include age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including psychotherapeutics. Respondents were also asked about substance abuse treatment history, illegal activities, problems resulting from the use of drugs, personal and family income sources and amounts, need for treatment for drug or alcohol use, criminal record, and needle-sharing. Questions on mental health and access to care, which were introduced in the 1994-B questionnaire (see NATIONAL HOUSEHOLD SURVEY ON DRUG ABUSE, 1994), were retained in this administration of the survey. In 1996, the section on risk/availability of drugs was reintroduced, and sections on driving behavior and personal behavior were added. Demographic data include sex, race, age, ethnicity, marital status, educational level, job status, income level, veteran status, and current household composition. This study has 1 Data Set.</p>
Compound 527009: 4''-Methoxy fentanyl

Chemical compound data from PubChem database. IUPAC Name: N-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]-N-phenylpropanamide. Molecular Formula: C23H30N2O2. Molecular Weight: 366.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
A survey of physicians knowledge regarding awareness of maternal alcohol use and the diagnosis of FAS.

Background
          Alcohol is the most widely used drug in the world that is a human teratogen whose use among women of childbearing age has been steadily increasing. It is also probable that Fetal Alcohol Syndrome is under diagnosed by physicians. The objectives of this study were twofold: 1) to evaluate the experience, knowledge and confidence of family physicians with respect to the diagnosis of FAS and 2) to evaluate physicians awareness of maternal drinking patterns.
        
        
          Methods and Participants
          A multiple choice anonymous questionnaire was sent to a randomly selected group of family physicians in the Metropolitan Toronto area.
        
        
          Results
          There was a 73% (75/103) total response rate; Overall, 6/75 (8%) of family physicians reported that they had actually diagnosed a child with FAS. 17.9% had suspicions but did not make a diagnosis and 12.7% reported making a referral to confirm the diagnosis. Physician rated confidence in the ability to diagnosis FAS was low, with 49% feeling they had very little confidence. 75% reported counselling pregnant women and 60.8% reported counselling childbearing women in general on the use of alcohol. When asked what screening test they used to detect the use of alcohol, 75% described frequency/quantity. Not a single respondent identified using the current accepted screening method for alcohol use (TWEAK) which is recommended by The Centre for Addiction and Mental Health.
        
        
          Conclusions
          Family physicians do not feel confident about diagnosing FAS. None of the physicians were aware of the current screening methods to accurately gage alcohol use in pregnant and childbearing women
Daily Census Tract-Level Ozone Concentrations, 2006-2010

This dataset provides modeled predictions of ozone levels from the EPA's Downscaler model. Data are at the census tract level for 2006-2010. These data are used by the CDC's National Environmental Public Health Tracking Network to generate air quality measures. Census tract-level datasets contain estimates of the mean predicted concentration and associated standard error. Please refer to the metadata attachment for more information.

Learn more about outdoor air quality on the Tracking Network's website: https://ephtracking.cdc.gov/showAirLanding.action.

By using these data, you signify your agreement to comply with the following requirements:
1. Use the data for statistical reporting and analysis only.
2. Do not attempt to learn the identity of any person included in the data and do not combine these data with other data for the purpose of matching records to identify individuals.
3. Do not disclose of or make use of the identity of any person or establishment discovered inadvertently and report the discovery to: trackingsupport@cdc.gov.
4. Do not imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources and CDC unless the data user and data source are formally collaborating.
5. Acknowledge, in all reports or presentations based on these data, the original source of the data and CDC.
6. Suggested citation: Centers for Disease Control and Prevention. National Environmental Public Health Tracking Network. Web. Accessed: insert date. www.cdc.gov/ephtracking.
Compound 528648: Bis(trimethylsilyl) 3-trimethylsilyloxyoctanedioate

Chemical compound data from PubChem database. IUPAC Name: bis(trimethylsilyl) 3-trimethylsilyloxyoctanedioate. Molecular Formula: C17H38O5Si3. Molecular Weight: 406.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529740: Methyl 2,4-dichloro-2-bromo-3-oxobutanoate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-bromo-2,4-dichloro-3-oxobutanoate. Molecular Formula: C5H5BrCl2O3. Molecular Weight: 263.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400237-T1: [Translated] DISC IMPLANT

The invention relates to an artificial intervertebral disc for placement between adjacent vertebrae. The artificial intervertebral disc is preferably designed to restore disc height and lordosis, allow for a natural range of motion, absorb shock and provide resistance to motion and axial compression. Furthermore, the intervertebral disc may be used in the cervical, the thoracic, or the lumber regions of the spine. The artificial intervertebral disc may include either singularly or in combination: an interior at least partially filled with a fluid; a valve for injecting fluid into the interior of the disk; a central region having a stiffness that is preferably greater than the stiffness of the outer regions thus enabling the disc to pivot about the central region. The central pivot may be formed by a center opening, a central chamber, an inner core or a central cable.
Amlodipine and valsartan

Amlodipine and Valsartan is a prescription medication combining two drugs to treat high blood pressure. Amlodipine relaxes blood vessels, while valsartan blocks a hormone that tightens them. Available as oral tablets in strengths like 5mg/160mg or 10mg/320mg, manufactured by Lupin Pharmaceuticals under ANDA202829. This information was generated using AI and is provided for informational and research purposes only.
How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2)

Background
          The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascular complications in elderly patients with isolated systolic hypertension. In an attempt to confirm the safety of long-term antihypertensive therapy based on a dihydropyridine, the Syst-Eur patients remained in open follow-up after the end of Syst-Eur 1. This paper presents the second progress report of this follow-up study (Syst-Eur 2). It describes BP control and adherence to study medications.
        
        
          Methods
          After the end of Syst-Eur 1 all patients, treated either actively or with placebo, were invited either to continue or to start antihypertensive treatment with the same drugs as previously used in the active treatment arm. In order to reach the target BP (sitting SBP <150 mmHg), the first line agent, nitrendipine, could be associated with enalapril and/or hydrochlorothiazide.
        
        
          Results
          Of the 3787 eligible patients, 3516 (93%) entered Syst-Eur 2. At the last available visit, 72% of the patients were taking nitrendipine. SBP/DBP at entry in Syst-Eur 2 averaged 160/83 mmHg in the former placebo group and 151/80 mmHg in the former active-treatment group. At the last follow-up visit SBP/DBP in the patients previously randomised to placebo or active treatment had decreased by 16/5 mmHg and 7/5 mmHg, respectively. The target BP was reached by 74% of the patients.
        
        
          Conclusion
          Substantial reductions in systolic BP may be achieved in older patients with isolated systolic hypertension with a treatment strategy starting with the dihydropyridine calcium-channel blocker, nitrendipine, with the possible addition of enalapril and/or hydrochlorothiazide.
Exposure to the antimicrobial chemical triclosan disrupts keratinocyte function and skin integrity in a model of reconstructed human epidermis

Triclosan is an antimicrobial chemical incorporated into products that are applied to the skin of healthcare workers. Exposure to triclosan has previously been shown to be immunomodulatory and associated with allergic disease. Additionally, we have shown that exposure to triclosan dermally activates the NLRP3 inflammasome and disrupts the skin barrier integrity in mice. The skin is the largest organ in the body and plays an important role as a physical barrier and regulator of the immune system. Alterations in the barrier and immune regulatory functions of the skin have been demonstrated to increase the risk of sensitization and development of allergic disease. In this study, the impact of triclosan exposure on the skin barrier and keratinocyte function was investigated using a model of reconstructed human epidermis. The apical surface of reconstructed human epidermis was exposed to triclosan once for 6, 24, or 48 hours or daily for 5 consecutive days.
QHP Landscape Instructions PY2024 Medical SHOP

The Medical SHOP Market file of the QHP Landscape Files contains information on certified medical plans offered through an Exchange to employers in the Small Business Health Options Program (SHOP) market. These plans are also known as Qualified Health Plans (QHPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.
Compound 525530: (3-Chloro-4-phenylpropoxy-phenyl)-acetic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2-[3-chloro-4-(2-phenylethoxy)phenyl]acetate. Molecular Formula: C17H17ClO3. Molecular Weight: 304.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Setting of graded levels of a protein in yeast by a t-degron technique as applied to phosphoglycerate mutase

Background
          Setting of graded levels of a protein for in vivo studies by controlled gene expression has inconveniences, and we here explore the use of the t-degron technique instead.
        
        
          Results
          In a yeast t-degron (ubiquitin-argDHFRts)- phosphoglycerate mutase (GPM1) fusion strain, increasing periods of exposure to the non-permissive temperature 37°C, even in the presence of cycloheximide, gave decreasing function, as assessed at 23°C in vivo by glucose metabolism and confirmed by immunoblot.
        
        
          Conclusion
          An ideal system would set a range of lower levels of a protein, do so without compensating protein synthesis, and give stable activity for in vitro comparisons. Although the first two aims appear obtainable, the third was not in this example of the application, limiting its uses for some but not all purposes.
Compound 526736: Diethylene glycol, nonyl ether, acetate

Chemical compound data from PubChem database. IUPAC Name: 2-(2-nonoxyethoxy)ethyl acetate. Molecular Formula: C15H30O4. Molecular Weight: 274.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401126-T1: [Translated] HEATING OF MULTI-CHAMBER CONTAINERS

A device for heating or cooling multiple single chamber containers or a multi-chamber container. The device includes: a unitary heat or cold source providing a source of heat or cold; heat exchange elements in thermal communication with the heat or cold source and extending away from the heat or cold source; a thermal barrier between each of said heat exchange elements to thermally isolate the heat exchange elements from each other. Each heat exchange element is thermally associated with one or more chambers that are different from one or more chambers associated with other heat exchange elements to thermally isolate the chambers from each other. Preferably the container is a sample or reagent container used in a clinical analyzer, such as a multi-chamber reaction cuvette or a multi-chamber microtiter plate. An incubator assembly, preferably usable in a clinical analyzer, can include the device for heating or cooling.
Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling

Background:
          Ventilator-associated bacterial pneumonia (VAP) is a important intensive care unit (ICU)-acquired infection in mechanically ventilated patients. Early and correct diagnosis of VAP is difficult but is an urgent challenge for an optimal antibiotic treatment. The aim of the study was to evaluate the incidence and microbiology of ventilator-associated pneumonia and to compare three quantitative bronchoscopic methods for diagnosis.
        
        
          Methods:
          A prospective, open, epidemiological clinical study was performed in a surgical ICU. In a prospective study, 279 patients admitted to a 14-bed surgical ICU during a 1-year period were evaluated with regard to VAP. Three quantitative culture bronchoscopic techniques for identifying the etiological agent were compared [bronchoalveolar lavage (BAL), protected specimen brush (PSB) and bronchoscopic tracheobronchial secretion (TBS)].
        
        
          Results:
          Among 103 long-term ventilated patients, 49 (48%) developed one or more VAPs (a total of 60 VAPs). The incidence was 24 VAPs per 100 ventilated patients or 23 VAPs per 1000 ventilator days. BAL, PSB and TBS with quantitative measurements were equivalent in identifying the bacterial etiology. The VAP was caused predominantly by Staphylococcus aureus in 38% of cases, followed by Pseudomonas aeruginosa in 10%, Haemophilus influenzae in 10% and Klebsiella sp. in 9%. We did not find an increased mortality rate in patients undergoing long-term ventilation who acquired VAP in comparison with patients without VAP.
        
        
          Conclusion:
          For the identification of the microbiological etiology of VAP, one of three available bronchoscopic methods analysed by quantitative measurements is sufficient. In our study, quantitative bronchoscopic tracheal secretion analysis was very promising. Before accepting this method as a standard technique, other studies will have to confirm our results.
Patent AT-E399599-T1: [Translated] PAINT FEEDING DEVICE AND PAINTING DEVICE

A paint or varnish feeder for a painting device comprises at least one manifold ( 13; 33 ; . . . ) with openings or small dispensing channels ( 15; 55 ; . . . ). The at least one manifold ( 13; 33 ; . . . ) is fed through at least one pipe ( 16 ; . . .) starting from a container in which a slight pressure is created. The small dispensing channels ( 15; 55 ; . . . ) can have various configurations in the various embodiments.
Compound 526165: Diethyl 3-cyano-phenyl phosphate

Chemical compound data from PubChem database. IUPAC Name: (3-cyanophenyl) diethyl phosphate. Molecular Formula: C11H14NO4P. Molecular Weight: 255.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529896: Naringenin, TMS

Chemical compound data from PubChem database. IUPAC Name: 5,7-bis(trimethylsilyloxy)-2-(4-trimethylsilyloxyphenyl)-2,3-dihydrochromen-4-one. Molecular Formula: C24H36O5Si3. Molecular Weight: 488.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530763: m-Methoxybenzoic acid, 2-bromo-4-fluorophenyl ester

Chemical compound data from PubChem database. IUPAC Name: (2-bromo-4-fluorophenyl) 3-methoxybenzoate. Molecular Formula: C14H10BrFO3. Molecular Weight: 325.13. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Vancomycin-Resistant Enterococci (VRE) Bloodstream Infections in California Hospitals

California Health and Safety Code section 1288.55(a)(1) requires general acute care hospitals to report all cases of vancomycin-resistant enterococci (VRE) bloodstream infections (BSI) to the California Department of Public Health (CDPH). Hospitals report VRE data to CDPH via the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) following NHSN protocols and definitions. 

CDPH downloads California hospital VRE BSI data from NHSN and analyzes the data to describe prevention progress in an annual public report of healthcare-associated infections. CDPH publishes annual VRE BSI data in datasets that include the number of VRE BSI reported by each California hospital in the specified reporting year and the hospital-onset VRE BSI rate. The VRE BSI rate is calculated by dividing the number of cases by the total number of patient days; the rate is then reported per 10,000 patient days. VRE BSI rates are not risk adjusted because there are no such methods available at this time. Aggregate mean rates used for comparisons are stratified by hospital type (and for community hospitals, by bed size). The unadjusted VRE BSI rates herein are affected by the clinical services provided, infection control practices, and surveillance methods. 

Detailed information about the variables included in each dataset are described in the accompanying data dictionaries for the year of interest.

For general information about NHSN, surveillance definitions, and reporting requirements for VRE, please visit: https://www.cdc.gov/nhsn/index.html 

To link the CDPH facility IDs with those from other Departments, including HCAI, please reference the "Licensed Facility Cross-Walk" Open Data table at: https://data.chhs.ca.gov/dataset/licensed-facility-crosswalk.

For information about healthcare-associated infection prevention progress in California hospitals and statewide prevention goals, please visit: https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/AnnualHAIReports.aspx
Patent AT-E400900-T1: [Translated] METHOD FOR PRODUCING A PHOTOVOLTAIC CELL BASED ON THIN FILM SILICON

The invention concerns a method for making a photovoltaic cell based on thin film silicon, which consists in providing a heterojunction by depositing on a support at least one first P- (or N-) doped amorphous silicon layer (13) and a second N- (or P-) doped amorphous silicon layer (14), in crystallizing, at least partly, the at least one first layer (13) using a technology for crystallizing silicon by pulsed electronic beam.
West Virginia (WV)

This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for West Virginia for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Patent AT-E400591-T1: [Translated] POLYMERIZATION PROCESS

This invention relates to a process to polymerize olefins comprising: contacting: (i) propylene and (ii) a mixture comprising, optionally ethylene, and three or more different alpha olefins having 4 to 20 carbon atoms, wherein at least one alpha olefin is present at Z percent or more, based upon the weight of the mixture, where Z=Y+X, where X=(100 divided by the number of alpha olefins present in the mixture) and Y equals 1 to 75, where Z is not more than 95%, with (iii) a metallocene catalyst system.
National Post-acute and Long-term Care Study: Adult Day Service Provider Restricted Dataset

The National Post-acute and Long-term Care Study (NPALS) is a biennial study of major post-acute and long-term care providers and their services users. Seven provider settings are in included. NPALS collects survey data on the residential care community and adult day services sectors, and uses administrative data (available from CMS) for home health, nursing home, hospice, inpatient rehabilitation, and long-term care hospital sectors.
The goals of the study are to: estimate the supply of paid, regulated post-acute and long-term care services providers; estimate key policy-relevant characteristics and practices of these providers; estimate the number of post-acute and long-term care services users; estimate key policy-relevant characteristics of these users; produce national and state estimates where feasible; compare across provider sectors; and monitor trends over time.